-GENFIT announces plans to conduct registered Public Offering in the United States
Nov 20, 2018 - ENP Newswire
Lille - GENFIT SA (Euronext: GNFT), a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases, today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares ('ADSs'), in the United States and has confidentially submitted a draft registration statement on Form F-1 to the U.S. ...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
